Ready to Uncover Precision with Jeuveau^® (prabotulinumtoxinA-xvfs)?

About Evolus™

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. Its first commercial product is Jeuveau^®, a proprietary neurotoxin formulation used in adults to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). Supported by a unique business model and focus on the millennial demographic, Evolus is increasing its presence in the fast-growing aesthetic neurotoxin market while pursuing a strategy of becoming a leading, multi-product aesthetics company.

About Jeuveau^®

Jeuveau^® is a modern-made neurotoxin providing:

• A precise, tight field of effect.¹
• Fast-acting, long-lasting results. Jeuveau^® demonstrated results in as little as 2 days and lasting up to 5 months.²
• Real-world patient satisfaction^* backed by clinical data.^†
  • ^*94% of patients were satisfied with their overall Jeuveau^® treatment.³
  • ^†94.5% of patients rated themselves as much improved or improved at day 30.²

Every vial of Jeuveau^® comes packed with precision

• Jeuveau^® is an FDA-approved 900-kDa modern-made neurotoxin with a precise, tight field of effect.¹
• The precision of Jeuveau^® puts control into the hands of the provider to help drive consistent outcomes with fast acting, long lasting results through intramuscular injection.¹
• Jeuveau^® was studied in over 2,100 subjects in 5 clinical trials, including the largest head-to-head Phase 3 trial of glabellar lines vs Botox^® Cosmetic (non-inferiority study in Europe/Canada).^4-9

See the full Prescribing Information

Clinical Studies

Learn more by reviewing the following clinical studies:

Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies (published in Dermatologic Surgery, 2019)

A Phase III Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines (published in Aesthetic Surgery Journal, 2020)

Order Now

References:

1. Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15.
2. Rzany B. A multicenter , randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020;40(4):413-429.
3. Jeuveau Experience Treatment (J.E.T.) Interim Data Report, 12/16/2019; Evolus, Inc.
4. Beer K. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: resultsfrom 2 identical phrase III studies. Dermatol Surg. 2019;45(11):1381-1393.
5. Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA.
6. Data on file; CSR EV-002, BLA761085. Evolus, Inc., Newport Beach, CA.
7. Data on file; CSR EV-003, BLA761085. Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA.
8. Data on file; CSR EV-004, BLA761085. Evolus, Inc., Newport Beach, CA.
9. Data on file; CSR EV-006, BLA761085. Evolus, Inc., Newport Beach, CA.